Could a low-dose drug help relieve chronic fatigue and Long-COVID?
NCT ID NCT06257420
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether low-dose rapamycin can reduce symptoms and improve quality of life in people with ME/CFS or Long-COVID. About 150 participants will take the drug as prescribed by their doctor and complete surveys and blood tests over time. The goal is to see if the drug helps with fatigue, daily function, and overall well-being.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LONG COVID are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Bateman Horne Center
Salt Lake City, Utah, 84102, United States
-
Center For Complex Diseases
Palo Alto, California, 94040, United States
-
Center For Complex Diseases
Seattle, Washington, 98109, United States
-
Sierra Internal Medicine
Incline Village, Nevada, 89451, United States
-
The Mayo Clinic
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Could exercise retrain the heart in long COVID?
- Can brain games and gentle currents lift long COVID brain fog?
- Can brain training zap long COVID brain fog?
- Ear device zaps vagus nerve in bid to quiet long COVID fatigue and brain fog
- Smartphone therapy could ease long COVID's mental toll